Applications of Tyrphostin AG 490 in Industrial Manufacturing

Tyrphostin AG 490, a well-characterized inhibitor of JAK2 and EGFR tyrosine kinases, has been adopted in various industrial segments for its specific biochemical attributes. Our company supplies this material for targeted applications that require strict compliance, process consistency, and functional performance across pharmaceutical development, translational research, cell therapy manufacturing, advanced diagnostic systems, and preclinical testing formulations. Below you will find in-depth application scenarios detailing regulatory frameworks, formulation guidance, process positioning, and resulting finished product categories based on current industrial practices.

1. Small Molecule Drug Research and Development

Pharmaceutical companies integrate this material as a reference inhibitor and mechanistic probe in their early-stage R&D aimed at kinase target validation and novel therapeutic screening. The use spans from initial biochemical assays to cellular proof-of-concept studies, supporting structure-activity relationship mapping and off-target risk assessment within regulated frameworks for clinical candidate nomination.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP General Chapter <795>: Pharmaceutical Compounding – Nonsterile Preparations
• European Pharmacopeia (Ph. Eur.) reference standards usage
• FDA cGMP (21 CFR 210, 211) for R&D lots

Typical usage ratio

• Common screening concentrations: 1–50 μM in biochemical assays
• Cell-based system dosing: 1–20 μM, adjusted based on cell viability and signal transduction endpoints

Downstream process integration

• Dissolution in DMSO or buffered solvents for HTS inclusion
• Direct addition to microplate assays during kinase activity studies
• Supplementation into pharmacological screening platforms before analytical readout

Final product types

• Kinase inhibitor libraries
• Pharmaceutical screening kits
• Preclinical reference standards for assay development
• Validated hit compounds for later optimization

2. Cell Signal Pathway Analysis in Translational Research

Core life sciences facilities and CROs include Tyrphostin AG 490 in their investigative workflows for dissecting JAK/STAT and EGFR-driven signaling. Its defined inhibitory profile supports time-course studies, pathway modulation experiments, and functional rescue assays for mechanistic research, all within controlled laboratory and regional biosafety frameworks.

Industry compliance standards

• GLP (Good Laboratory Practice) for non-clinical research (OECD/US EPA 21 CFR 58)
• EU Directive 2010/63/EU for laboratory animal use (when in vivo technique is employed)
• ISO 17025: Testing and Calibration Laboratories

Typical usage ratio

• Cellular stimulation assays: 5–20 μM per experimental protocol, with optimization by assay endpoint
• Pulsed exposure or chronic treatments adjusted based on pathway activation kinetics

Downstream process integration

• Media supplementation prior to cytokine/growth factor stimulation
• Dosing during sample preparation for cell lysis and extract
• Parallel addition with pathway inducers for multiplex signal analysis

Final product types

• Cell signaling research assay kits
• Biochemical pathway modulation panels
• Validated phospho-protein arrays
• Publication-ready mechanistic research data sets

3. GMP Manufacturing of Investigational Cell Therapy Reagents

Cell processing centers and ATMP manufacturers utilize this compound for ex vivo modulation of cell populations during investigational T-cell and hematopoietic processes. Here, precise control of JAK/STAT signaling via small molecule inhibitors is critical to condition cell state, support expansion, or modulate activation under strict GMP and biosafety compliance, particularly for Phase I/II studies.

Industry compliance standards

• EU GMP Annex 1 and Annex 2 (Biological and ATMP requirements)
• US FDA CFR 21 Part 1271 (Human Cells, Tissues, and Cellular Products)
• PIC/S Guidance on GMP for Advanced Therapy Medicinal Products
• WHO TRS 1019: GMP for biotherapeutic products

Typical usage ratio

• Ex vivo modulation: 5–15 μM in culture medium, scheduled with activation or expansion steps
• Adjustment per donor cell phenotype and intended product attributes

Downstream process integration

• Added during cell priming or activation phase (e.g., CAR-T cell engineering)
• Pulse treatment during cell expansion for signal pathway modulation
• Integration before final formulation during washout or harvest for quality control

Final product types

• Engineered T cell lots for clinical research
• Genetically modified hematopoietic cell products
• QC-validated cell banks for investigational use
• Conditioned cell therapy research reagents

4. Diagnostic and Biomarker Assay Reagent Production

Diagnostic reagent manufacturers incorporate Tyrphostin AG 490 into proprietary kits for in vitro analysis of kinase pathway status, including phosphorylation-dependent ELISA panels, Western blot controls, and reference calibrators for high-sensitivity clinical research diagnostics. The integration supports accurate signal discrimination, panel standardization, and validation according to ISO and regional diagnostic manufacturing regulations.

Industry compliance standards

• ISO 13485: Medical Devices – Quality Management Systems for Regulatory Purposes
• IVDR (EU Regulation 2017/746 on in vitro diagnostic medical devices)
• US FDA 21 CFR 820 (Quality System Regulation for medical devices)

Typical usage ratio

• Reference inhibitor concentration: 2–10 μM within test kits, depending on sample matrix and detection platform
• Lot qualification per batch with platform-specific adjustments

Downstream process integration

• Integration during final buffer formulation for ELISA kits
• Incorporation into control and calibration vials for diagnostic test panels
• Stabilization with protein carriers or excipients for kit assembly

Final product types

• Signal transduction diagnostic reagent kits
• Phosphorylation-specific ELISA controls
• Standardized assay calibration sets
• Immunoassay verification panels for laboratory diagnostics

5. Preclinical Animal Model Research Formulation

Organizations developing rodent or zebrafish disease models harness this inhibitor in preclinical testing regimens to dissect cytokine, inflammation, or tumor signaling events, optimizing formulations for pharmacodynamic studies. It enters through precisely dosed feeding or injection regimes adhered to by institutional animal care, regional regulatory bodies, and preclinical study sponsors.

Industry compliance standards

• AAALAC accreditation for animal care facilities
• Guide for the Care and Use of Laboratory Animals (National Research Council, US)
• Institutional Animal Care and Use Committee (IACUC) protocol approval
• OECD Guidelines for Testing of Chemicals adoption in study design

Typical usage ratio

• Animal dosing regimens: 1–5 mg/kg by intraperitoneal injection or oral gavage, adapted to species and model
• Solvent and vehicle optimization based on study length and bioavailability

Downstream process integration

• Preparation of dosing solutions immediately before animal administration
• Aliquoting and storage under light- and temperature-controlled conditions before use
• Monitoring of residual compound and metabolites during study analysis

Final product types

• Disease model formulation batches for sponsor studies
• Pathway validation sets for drug target research
• Biochemical reference standard dosing solutions
• Validated control arms for translational pharmacology programs